SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study)
Cephalalgia · 2026-06 · 46 (6)
DOI: 10.1177/03331024261435922 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cephalalgia, online erschienen am 26.06.2026. Verfasst von Claudia Altamura und 38 weiteren Autor:innen. Beteiligte Einrichtung: Headache and Neurosonology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide Receptor Antagonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
The improved prevention of migraine, driven by the introduction of calcitonin gene-related peptide (CGRP)-targeted therapies, has prompted the International Headache Society (IHS) to propose new goals in migraine management. This study aimed to evaluate the safety and effectiveness of atogepant for migraine prevention over 24 weeks, in accordance with the IHS-defined goals.
Methods
This is a multicenter, prospective, observational, real-world study on patients starting atogepant 60 mg for migraine prevention. We describe efficacy and safety outcomes at weeks 9–12 (T3) and 21–24 (T6) relative to baseline (T0) from the initiation of atogepant treatment. We also report the proportion of patients achieving migraine freedom, optimal, modest or insufficient control according to the IHS position paper categories.
Results
One hundred twenty-eight ( n = 128) patients (63 (49.2%) with chronic migraine, 115 (89.9%) female, aged 48.3 ± 13.3 years) from 17 centers were analyzed. Monthly migraine days decreased from 16.5 ± 8.5 at T0 to 8.0 ± 8.4 at T3 ( p < 0.001 vs. T0) and 8.6 ± 9.2 at T6 ( p < 0001 vs. T0, p = 0.265 compared to T3). Overall, 64.8% of patients were responders (at least 50% reduction in monthly migraine days from T0) at T3 and 61.7% at T6; 81.9% of responders at T3 maintained the responder status at T6, while 24.4% of patients among non-responders at T3 became responders at T6. At T3 and T6, 39.1% of the entire cohort achieved at least optimal migraine control (20.6% in chronic migraine and 56.9% in episodic migraine).
Conclusions
The STAR study demonstrates, in a real-world setting, the safety and the sustained effectiveness of atogepant 60 mg over 24 weeks and indicates that more than one-third of treated patients can achieve at least optimal disease control, with markedly better outcomes in episodic than in chronic migraine. Trial Registration The study was preregistered on clinicaltrial.gov, NCT06414044.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Headache and Neurosonology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy.
- Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Rome, Italy.
- Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena, Italy.
- Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico Di Modena, Modena, Italy.
- Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Polo Pontino, Latina, Italy.
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
ORCID-Profile: Claudia Altamura, Luigi Francesco Iannone, Gabriele Sebastianelli, Marilena Marcosano, Federico De Santis, Raffaele Ornello, Licia Grazzi, Danilo Antonio Montisano, Antonio Munafò, Michele Trimboli, Antonio Russo, Marina Romozzi, Paola Merlo, Innocenzo Rainero, Giada Giuliani, Luisa Fofi, Gloria Vaghi, Delfina Ferrandi, Stefania Battistini, Gianluca Coppola, Simona Guerzoni, Simona Sacco, Cristina Tassorelli, Fabrizio Vernieri
Zitieren
APA
Altamura, C., Iannone, L. F., Castro, F. L., Sebastianelli, G., Marcosano, M., Santis, F., Corrado, M., Ornello, R., Grazzi, L., Montisano, D. A., Cesaris, F., Munafò, A., Avino, G., Trimboli, M., Albanese, M., Russo, A., Silvestro, M., Volta, G. D., Romozzi, M., …, & Italian Headache Registry (RICe) Study Group (2026). SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study). Cephalalgia, 46(6). https://doi.org/10.1177/03331024261435922
Vancouver
Altamura C, Iannone LF, Castro FL, Sebastianelli G, Marcosano M, Santis F, et al. SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study). Cephalalgia. 2026;46(6). doi:10.1177/03331024261435922
BibTeX
@article{Altamura2026,
author = {Altamura, Claudia and Iannone, Luigi Francesco and Castro, Flavia Lo and Sebastianelli, Gabriele and Marcosano, Marilena and Santis, Federico De and Corrado, Michele and Ornello, Raffaele and Grazzi, Licia and Montisano, Danilo Antonio and Cesaris, Francesco De and Munafò, Antonio and Avino, Gianluca and Trimboli, Michele and Albanese, Maria and Russo, Antonio and Silvestro, Marcello and Volta, Giorgio Dalla and Romozzi, Marina and Calabresi, Paolo and Boccalini, Alberto and Merlo, Paola and Prudenzano, Maria Pia and Valente, Maria Rosaria and Rainero, Innocenzo and Giuliani, Giada and Altieri, Marta and Fofi, Luisa and Doretti, Alberto and Vaghi, Gloria and Pistoia, Francesca and Ferrandi, Delfina and Battistini, Stefania and Coppola, Gianluca and Guerzoni, Simona and Sacco, Simona and Tassorelli, Cristina and Vernieri, Fabrizio and Italian Headache Registry (RICe) Study Group, Italian Headache Registry (RICe) Study Group},
title = {SafeTy and effectiveness of Atogepant accoRding to the IHS outcome categories: A multicentric, prospective observational study in real life (the 24-week STAR study)},
journal = {Cephalalgia},
year = {2026},
volume = {46},
number = {6},
doi = {10.1177/03331024261435922}
}
EUVIMED